RASSF1 and prostate carcinoma: The ConfirmMDx, which is based on the evaluation of the promoter methylation levels of three genes, namely GSTP1, APC and RASSF1 in prostate biopsy samples, was designed to identify men at lower risk for prostate cancer, thus avoiding repeated biopsies [100].